Castle Biosciences, Inc.

    Jurisdiction
    United States
    ISIN
    US14843C1053 (CSTL)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Read full profile

    Fundamentals

    Net revenue
    €295.35M
    Gross margin
    85.0%
    EBIT
    -€19.66M
    EBIT margin
    -6.7%
    Net income
    -€8.07M
    Net margin
    -2.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A -€47.80M +492.0%
    €291.78M -€49.03M +2.6%
    €320.37M +9.8% -€43.63M -11.0%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    MAETZOLD DEREK J Pres. & Chief Exec. Officer -1.3K $23.93 -$32.04K
    Oelschlager Kristen M Chief Operating Officer -31K $21.69 -$665.54K
    MAETZOLD DEREK J Pres. & Chief Exec. Officer -1.3K $20.04 -$26.83K
    MAETZOLD DEREK J Pres. & Chief Exec. Officer -43K $19.50 -$838.87K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 701K $14.04M +16K Buy

    Earnings Calls

    Latest earnings call: May 2, 2024 (Q1 2024)

    Add to watchlist

    Notifications